Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has received an average rating of “Hold” from the eight brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $11.26.

ANTH has been the subject of a number of research reports. Zacks Investment Research upgraded shares of Anthera Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. ValuEngine cut shares of Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Jefferies Group LLC restated a “hold” rating and set a $2.25 target price on shares of Anthera Pharmaceuticals in a research note on Monday, May 15th.

Anthera Pharmaceuticals (NASDAQ ANTH) traded down 2.13% on Friday, hitting $1.84. 104,057 shares of the stock traded hands. The stock’s market cap is $18.54 million. Anthera Pharmaceuticals has a 52 week low of $1.54 and a 52 week high of $32.00. The firm’s 50 day moving average is $1.79 and its 200 day moving average is $1.06.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.47) by $0.56. Equities analysts anticipate that Anthera Pharmaceuticals will post ($5.06) earnings per share for the current year.

A number of hedge funds have recently modified their holdings of ANTH. Geode Capital Management LLC boosted its stake in shares of Anthera Pharmaceuticals by 16.2% in the first quarter. Geode Capital Management LLC now owns 355,172 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 49,391 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 335,595 shares during the period. UBS Group AG boosted its stake in shares of Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 33,901 shares during the period. Sabby Management LLC boosted its stake in shares of Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 1,665,655 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Anthera Pharmaceuticals by 49.1% in the first quarter. Vanguard Group Inc. now owns 2,691,639 shares of the biopharmaceutical company’s stock valued at $1,145,000 after buying an additional 886,910 shares during the period.

TRADEMARK VIOLATION WARNING: “Anthera Pharmaceuticals, Inc. (ANTH) Receives Consensus Rating of “Hold” from Brokerages” was reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/06/16/anthera-pharmaceuticals-inc-anth-receives-consensus-rating-of-hold-from-brokerages.html.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.